Valneva SE (EPA: VLA)

France flag France · Delayed Price · Currency is EUR
2.404
-0.010 (-0.41%)
Nov 11, 2024, 5:35 PM CET
-62.20%
Market Cap 390.34M
Revenue (ttm) 158.54M
Net Income (ttm) -7.42M
Shares Out 162.37M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 400,763
Open 2.430
Previous Close 2.414
Day's Range 2.392 - 2.478
52-Week Range 2.392 - 6.540
Beta 0.99
Analysts n/a
Price Target n/a
Earnings Date Nov 7, 2024

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 676
Stock Exchange Euronext Paris
Ticker Symbol VLA
Full Company Profile

Financial Performance

In 2023, Valneva SE's revenue was 153.71 million, a decrease of -57.46% compared to the previous year's 361.30 million. Losses were -101.43 million, -29.21% less than in 2022.

Financial Statements

News

Valneva reports nine-month results

5 days ago - Seeking Alpha

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 million Net Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 ...

5 days ago - GlobeNewsWire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Saint-Herblain (France), October 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that members of its senior leadership team will present dataset...

22 days ago - GlobeNewsWire

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech com...

27 days ago - GlobeNewsWire

Valneva Hosts Investor Day in New York City

Live event and webcast TODAY at 10 AM ET Saint Herblain (France), October 10, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an investor day today in New...

4 weeks ago - GlobeNewsWire

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Saint Herblain (France), October 3, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Ho...

5 weeks ago - GlobeNewsWire

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, t...

7 weeks ago - GlobeNewsWire

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Pr...

2 months ago - GlobeNewsWire

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject ...

2 months ago - GlobeNewsWire

Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine

The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.

2 months ago - MarketWatch

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and safety data from th...

2 months ago - GlobeNewsWire

Valneva reports 1H results

3 months ago - Seeking Alpha

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasing Net Profi...

3 months ago - GlobeNewsWire

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Saint-Herblain (France) and Schlieren (Zurich), August 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and LimmaTech Biologics AG, a clinical-stage biotech compan...

3 months ago - GlobeNewsWire

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine

Oslo, Norway, and Saint-Herblain, France, July 22, 2024—The Coalition for Epidemic Preparedness Innovations (CEPI) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, have...

4 months ago - GlobeNewsWire

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

On Wednesday, Pfizer Inc PFE and Valneva SE VALN announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidat...

4 months ago - Benzinga

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine...

4 months ago - GlobeNewsWire

Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®

Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorizati...

4 months ago - GlobeNewsWire

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Saint-Herblain (France), June 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors wer...

4 months ago - GlobeNewsWire

Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®

Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva's single-dose vac...

5 months ago - GlobeNewsWire

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined ...

5 months ago - GlobeNewsWire

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Saint-Herblain (France), June 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor confe...

5 months ago - GlobeNewsWire

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vac...

5 months ago - GlobeNewsWire

Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine

Saint Herblain (France), May 31, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of t...

5 months ago - GlobeNewsWire